Assessment of the effectiveness and safety of two-month oral supplementation with L-arginine depending on the type of lipid metabolism disorder in patients with atherosclerotic lower limb ischemia.

L-arginine supplementation significantly increased serum nitric oxide (NO) concentrations after both 30 and 60 days of treatment.

• Significant increases in NO levels were observed at day 30 and day 60 (p<0.001)
• Increases were observed across all subgroups receiving L-arginine compared with controls, including hypertriglyceridemia, hypercholesterolemia, and mixed hyperlipidemia subgroups
• The study group received oral L-arginine at a dose of 6 g/day
• Controls did not show significant changes in NO levels

L-arginine supplementation significantly increased total antioxidant status (TAS) after both 30 and 60 days of treatment.

• Significant increases in TAS levels were observed at day 30 and day 60 (p<0.001)
• Increases were consistent across all lipid disorder subgroups receiving L-arginine compared with controls
• The dose was 6 g/day of oral L-arginine over 60 days
• The finding supports improvement in oxidative balance with L-arginine supplementation

L-arginine supplementation significantly extended pain-free walking distance (PFWD) after both 30 and 60 days.

• Significant increases in PFWD were observed at day 30 and day 60 (p<0.001)
• Improvements in PFWD were observed across all subgroups receiving L-arginine compared with controls
• Participants had Fontaine stage II ischemia (intermittent claudication)
• The improvement indicates enhanced exercise tolerance with L-arginine treatment

L-arginine supplementation had no significant effect on the ankle-brachial index (ABI) in either limb.

• No significant effects were observed on ABI for either right or left limb
• Evaluations were performed at baseline, day 30, and day 60
• The lack of ABI change occurred despite improvements in functional walking capacity and oxidative stress markers
• This was consistent across all lipid disorder subgroups

L-arginine supplementation had no significant effect on lipid profile parameters, including total cholesterol, HDL cholesterol, LDL cholesterol, or triglycerides.

• No significant changes were observed in total cholesterol, HDL cholesterol, LDL cholesterol, or triglyceride concentrations
• Subgroups were specifically stratified by lipid disorder type: hypertriglyceridemia, hypercholesterolemia, and mixed hyperlipidemia
• The lipid-neutral effect was observed across all subgroups and both time points (day 30 and day 60)
• Dose was 6 g/day for 60 days in patients over 50 years of age

The study enrolled 100 patients with atherosclerotic lower limb ischemia, stratified by lipid metabolism disorder type.

• 100 patients total: 62 men and 38 women, all over 50 years of age with Fontaine stage II ischemia
• Patients were randomized into study and control groups
• Within both study and control groups, subgroups with hypertriglyceridemia, hypercholesterolemia, and mixed hyperlipidemia were identified
• Clinical parameters assessed included ABI, PFWD, serum NO concentration, TAS, and lipid profile
• Evaluations were performed at baseline, day 30, and day 60